Mode
Text Size
Log in / Sign up
N/A Completed N=54 Randomized Double-blind Treatment

Effect of Policosanol as Monotherapy and Adjunctive to Statin Therapy

High Cholesterol
Source: ClinicalTrials.gov NCT00510809 ↗
Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Jul 2012
Primary outcomePrimary: Lipid Profile — -5; -5; 2; -4 mg/dl

Summary

To determine the effects of policosanol on the cholesterol profile.

Outcome Measures

OutcomeResultp-value
PRIMARY
Lipid Profile
-5; -5; 2; -4; 4; 0 —
SECONDARY
Adverse Events Reported
6; 10; 5 —

Eligibility Criteria

Inclusion Criteria

  • LDL > 100
  • Male or Non-Pregnant Female. Women must be surgically sterile or postmenopausal and not using hormone replacement therapy (HRT) or using a stable, consistent HRT dose with intentions to continue therapy throughout the course of the study
  • Mentally competent to understand study rationale and protocol
  • Speak and read English
  • Currently receiving low to moderate dose statin therapy with plans to continue to the same dose for at least 8 weeks. Low to moderate dose statins include the following daily doses: atorvastatin ≤20 mg, fluvastatin ≤40 mg, lovastatin ≤40 mg, pravastatin ≤40 mg, rosuvastatin ≤10 mg, simvastatin ≤ 40 mg

Exclusion Criteria

  • LDL 500mg/day], bile-acid sequestrants, ezetimibe, fibrates and high-dose Omega-3 fish oils [>900mg of combined EPA/DHA daily])
  • Currently taking medications which have the potential to interact with policosanol (i.e. warfarin, high-dose aspirin)
  • Active liver disease or ALT level 2.5 times the upper limit of normal
  • Chronic disease involving hepatic, renal or coronary artery disease
  • Currently experiencing "flu-like" symptoms
  • Currently experiencing any form of acute physical injury
  • Acute psychiatric disorders
  • Immuno-compromised state
  • Currently taking systemic steroidal drugs
  • Currently pregnant or lactating
  • Females of childbearing potential
  • Dependence on alcohol or illicit drugs
  • Participation in any other clinical trial within the last 30 days
  • Displays s/s of acute systemic infection (oral temperature >100°F, WBC>12x10³/µL)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00510809). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search